NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

The NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) is a federal funding opportunity offered by the National Institute of Allergy and Infectious Diseases, which operates under the U.S. Department of Health and Human Services and the National Institutes of Health. NIAID’s mission focuses on advancing research to better understand, prevent, diagnose, and treat infectious, immunologic, and allergic diseases. This funding opportunity specifically supports investigator-initiated clinical trials that require enhanced oversight and are aligned with the institute’s strategic research priorities. The program reflects NIAID’s commitment to advancing biomedical science through both basic and applied clinical research, particularly in areas involving complex disease mechanisms and therapeutic development. The purpose of this funding opportunity is to support the full implementation of clinical trials that are already fully planned and ready to begin. These trials must involve human subjects assigned to interventions to evaluate biomedical or behavioral outcomes and must include features that necessitate enhanced oversight, such as the use of unlicensed products, non-routine interventions, or regulatory requirements like Investigational New Drug or Investigational Device Exemptions. The program allows for mechanistic studies within clinical trials, which are encouraged to deepen scientific understanding of disease processes and inform future therapies. Only one clinical trial may be proposed per application, and applicants must demonstrate readiness to implement the trial at the time of submission. Funding supports a wide range of allowable activities necessary for the execution and completion of clinical trials. These include recruitment and enrollment of participants, training of study personnel, data collection and management, laboratory analyses, regulatory compliance, study monitoring, and preparation of final reports. The funding mechanism is a cooperative agreement, meaning there is substantial involvement from NIH staff in oversight and coordination. Project periods are typically up to five years, although extensions to six or seven years may be permitted when justified by the complexity of the study, such as long follow-up periods or recruitment challenges. Budgets are not capped but must reflect the actual needs of the project. Eligibility for this opportunity is broad and inclusive, encompassing a wide array of applicant organizations. Eligible entities include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations, small businesses, federal and local government entities, tribal governments and organizations, school districts, housing authorities, and foreign organizations. Individual investigators with the appropriate expertise may serve as principal investigators in collaboration with eligible institutions. However, the program prohibits foreign subawards or subcontracts, though unfunded international collaborations and foreign components are permitted. The application process requires submission through federal systems such as Grants.gov, ASSIST, or institutional system-to-system solutions, with tracking through eRA Commons. Applicants must complete all required registrations, including SAM, UEI, and ORCID for principal investigators. Applications must adhere strictly to NIH guidelines and include detailed documentation such as a complete clinical protocol, data management and sharing plan, and data safety monitoring plan. Prior consultation with NIAID staff is strongly encouraged at least ten weeks before submission to ensure alignment with program goals and requirements. Applications are reviewed through NIH’s peer review process based on criteria including significance, innovation, rigor, feasibility, investigator expertise, and resource availability. Only meritorious applications proceed to funding consideration. The opportunity follows standard NIH submission cycles with multiple deadlines per year, and awards are contingent on appropriations and application quality. Key dates include an initial opening on September 5, 2026, with recurring submission deadlines in October, February, and June cycles annually through the expiration of the program in July 2029. Awardees are expected to comply with extensive reporting, regulatory, and oversight requirements throughout the project lifecycle. This includes clinical trial registration, data sharing, safety monitoring, and adherence to federal regulations. The cooperative agreement structure ensures ongoing collaboration between recipients and NIH staff, including milestone tracking and scientific guidance. This funding opportunity represents a significant investment in advancing clinical research infrastructure and generating impactful scientific knowledge in infectious and immune-related diseases.

Ensure trial readiness at submission; include complete protocol and monitoring plans; align with NIAID mission; consult program staff early